AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22611116 — intervention group
Group type: COMPARATOR
Intervention: M2: Cycled on and off CPAP with incremental time 'OFF'
Number of subjects: 177
Study 22611116 — intervention group
Group type: COMPARATOR
Intervention: M3: Cycled on and off CPAP with 2 mm nasal cannula support during 'OFF' periods
Number of subjects: 177
Study 20375719 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 28
Study 20375719 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 28
Study 18474025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high dosage oral ibandronate
Number of subjects: 0
Study 18474025 — intervention group
Group type: COMPARATOR
Intervention: Daily low dose ibandronate
Number of subjects: 0
Study 15513977 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole ('Arimidex') alone or in combination with tamoxifen
Number of subjects: 285
Study 15513977 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 285
Study 15513977 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound scanning (TVUS)
Number of subjects: 285
Study 15513977 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 285
Study 15513977 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness assessment
Number of subjects: 285
Study 11996196 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg
Number of subjects: 164
Study 11996196 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 5 mg
Number of subjects: 164
Study 10215737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of alendronate/day
Number of subjects: 24
Study 10215737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7630617 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic programme (BP) of standard autogenic relaxation exercises
Number of subjects: 23
Study 7630617 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced programme (AP) with special exercises in ocular relaxation and imagination of aqueous humour drainage
Number of subjects: 23
Study 7630617 — intervention group
Group type: EXPERIMENTAL
Intervention: Twenty-four-hour IOP profiles and water drinking test
Number of subjects: 23
Study 7630617 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reduction
Number of subjects: 23
Study 7630617 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 23
Study 2203289 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg)
Number of subjects: 55
Study 2203289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 318981 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole
Number of subjects: 328
Study 318981 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrantel pamoate
Number of subjects: 328
Study 318981 — intervention group
Group type: EXPERIMENTAL
Intervention: bephenium hydroxynaphthoate
Number of subjects: 328
Study 318981 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole
Number of subjects: 328
Study 318981 — intervention group
Group type: EXPERIMENTAL
Intervention: thiabendazole
Number of subjects: 328
Study 318981 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 328
Study 31317460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration through a nasopharyngeal airway and standard nasal cannula
Number of subjects: 135
Study 31317460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no apneic oxygenation)
Number of subjects: 135
Study 28067693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative S-ketamine bolus 0.5 mg/kg and infusion 0.25 mg·kg·h
Number of subjects: 150
Study 28067693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 28067693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative S-ketamine
Number of subjects: 150
Study 24251378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 144
Study 24251378 — intervention group
Group type: COMPARATOR
Intervention: Orlistat medication therapy plus low-fat diet
Number of subjects: 144
Study 24251378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 144
Study 23176716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri Prodentis
Number of subjects: 20
Study 23176716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21680990 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg/d
Number of subjects: 547
Study 21680990 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg/d
Number of subjects: 547
Study 21680990 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg/d plus glyburide
Number of subjects: 547
Study 21680990 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg/d plus glyburide
Number of subjects: 547
Study 21680990 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg/d plus thiazolidinedione
Number of subjects: 547
Study 21680990 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg/d plus thiazolidinedione
Number of subjects: 547
Study 21680990 — intervention group
Group type: COMPARATOR
Intervention: placebo add-on
Number of subjects: 547
Study 19395295 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression procedure guided by mean arterial pressure (experimental)
Number of subjects: 351
Study 19395295 — intervention group
Group type: COMPARATOR
Intervention: Compression procedure using 15 cubic centimeters of air (standard)
Number of subjects: 351
Study 16686723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg once daily)
Number of subjects: 513
Study 16686723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study 16686723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Number of subjects: 513
Study 14990524 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimony method intervention (n=66)
Number of subjects: 206
Study 14990524 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=71)
Number of subjects: 206
Study 14990524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 206
Study 11271790 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg daily) for 10 weeks
Number of subjects: 5
Study 9493923 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 22
Study 9493923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8199416 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) providing 41 +/- 2 kcal, 0.30 +/- 0.02 g N kg‐1.day‐1, and 40 mg pyridoxine for 14 days.
Number of subjects: 51
Study 8199416 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation at a dosage of 8.6 mg.kg‐1.day‐1.
Number of subjects: 51
Study 8199416 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not specified in detail).
Number of subjects: 51
Study 3593812 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride
Number of subjects: 36
Study 3593812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29886765 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened quitter self-identity
Number of subjects: 339
Study 29886765 — intervention group
Group type: COMPARATOR
Intervention: Control group (neutral)
Number of subjects: 339
Study 29886765 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support present
Number of subjects: 339
Study 29886765 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support absent
Number of subjects: 339
Study 27406028 — intervention group
Group type: EXPERIMENTAL
Intervention: FenuSMART™ (fenugreek extract) 1000 mg/day for 90 days
Number of subjects: 88
Study 27406028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 24356886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Xen infusion at 12 pmol · kg(‐1) · min(‐1)
Number of subjects: 10
Study 24356886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lo-Xen infusion at 4 pmol · kg(‐1) · min(‐1)
Number of subjects: 10
Study 24356886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Xen infusion for 90 or 300 min
Number of subjects: 10
Study 24356886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Xen infusion for 30 min
Number of subjects: 10
Study 24356886 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Xen infusion
Number of subjects: 10
Study 23614845 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobil‐O‐Graph
Number of subjects: 24
Study 23614845 — intervention group
Group type: COMPARATOR
Intervention: Spacelabs 90207
Number of subjects: 24
Study 23614845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both monitors
Number of subjects: 24
Study 20942615 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Lysteda)
Number of subjects: 278
Study 20942615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 18697894 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy intervention
Number of subjects: 0
Study 15855325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day) for 12 weeks
Number of subjects: 2
Study 12543751 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic mapping using a positional candidate gene approach on DNA samples from affected individuals.
Number of subjects: 9
Study 12543751 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination including A-scan and B-scan ultrasonography and electrophysiological testing.
Number of subjects: 9
Study 12543751 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening of candidate genes within the NNO1 locus.
Number of subjects: 9
Study 10551920 — intervention group
Group type: EXPERIMENTAL
Intervention: dopexamine (1 microg/kg/min)
Number of subjects: 34
Study 10551920 — intervention group
Group type: COMPARATOR
Intervention: placebo (0.9% NaCl)
Number of subjects: 34
Study 8733744 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual naming task using standardized line drawings
Number of subjects: 7
Study 8733744 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter fluency task
Number of subjects: 7
Study 1833813 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMP) administered at progressive doses for 8 days (maximum dosage 75 mg) in the evening at 6 p.m.
Number of subjects: 68
Study 1833813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose solution infusion) administered morning and evening.
Number of subjects: 68
Study 6801213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (600 mg/day)
Number of subjects: 88
Study 6801213 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (300 mg/day)
Number of subjects: 88
Study 31994431 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending-ascending method of TPD testing
Number of subjects: 35
Study 31994431 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending with randomization method of TPD testing
Number of subjects: 35
Study 31994431 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-point estimation (TPE) method
Number of subjects: 35
Study 30711528 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (200 mg bid)
Number of subjects: 8
Study 30711528 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8
Study 28624175 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 156
Study 28624175 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 156
Study 26256280 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral transcatheter aortic valve replacement (TF‐TAVR)
Number of subjects: 1521
Study 24637966 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 84
Study 24637966 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 84
Study 22021897 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DAS28 and MMP‐3‐driven therapy (T group)
Number of subjects: 243
Study 22021897 — intervention group
Group type: COMPARATOR
Intervention: Routine care (R group)
Number of subjects: 243
Study 22021897 — intervention group
Group type: COMPARATOR
Intervention: MMP‐3‐driven therapy (M group)
Number of subjects: 243
Study 19346511 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with 50 microg nicotine/puff
Number of subjects: 10
Study 19346511 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with 100 microg nicotine/puff
Number of subjects: 10
Study 19346511 — intervention group
Group type: COMPARATOR
Intervention: Cigarette
Number of subjects: 10
Study 19346511 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI)
Number of subjects: 10
Study 16854595 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked primes during ongoing pointing movements
Number of subjects: 0
Study 16854595 — intervention group
Group type: COMPARATOR
Intervention: Visible masks
Number of subjects: 0
Study 15351759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bienestar Health Program
Number of subjects: 1419
Study 15351759 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1419
Study 11224630 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed primary closure (E/DPC)
Number of subjects: 51
Study 11224630 — intervention group
Group type: COMPARATOR
Intervention: Primary closure (PC)
Number of subjects: 51
Study 11229224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (at lower doses)
Number of subjects: 0
Study 11229224 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 11229224 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 11229224 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 7811344 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAME); 2 g daily in 250 ml 0.15 M NaCl for 15 days
Number of subjects: 40
Study 7811344 — intervention group
Group type: COMPARATOR
Intervention: Control group (alcoholic patients without treatment)
Number of subjects: 40
Study 2898932 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride
Number of subjects: 25
Study 2898932 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate
Number of subjects: 25
Study 9511622 — intervention group
Group type: EXPERIMENTAL
Intervention: Myprodol (Ibuprofen, Paracetamol and Codeine phosphate)
Number of subjects: 52
Study 9511622 — intervention group
Group type: COMPARATOR
Intervention: Ponstan (Mefenamic acid)
Number of subjects: 52
Study 332607 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids containing Mg (OH)2, Al (OH)3 and CaCO3, administered after meals
Number of subjects: 0
Study 332607 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30648197 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (CGCL)
Number of subjects: 104
Study 30648197 — intervention group
Group type: COMPARATOR
Intervention: Guided surgery but conventional loading group (GSCL)
Number of subjects: 104
Study 30648197 — intervention group
Group type: COMPARATOR
Intervention: Guided surgery and immediate loading group (GSIL)
Number of subjects: 104
Study 28720140 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategy informed by stakeholders
Number of subjects: 400
Study 28720140 — intervention group
Group type: COMPARATOR
Intervention: Basic implementation strategy (intervention as usual)
Number of subjects: 400
Study 25888344 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Relaxation Technique (ART)
Number of subjects: 105
Study 25888344 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Intervention (MI)
Number of subjects: 105
Study 25888344 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature Video Application with Music (NVAM)
Number of subjects: 105
Study 25888344 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature Video Application without Music (NVA)
Number of subjects: 105
Study 25888344 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 105
Study 24377635 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1736
Study 24377635 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor academic achievement
Number of subjects: 1736
Study 24377635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-smoker
Number of subjects: 1736
Study 24377635 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a smoking friend
Number of subjects: 1736
Study 24377635 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception that smoking prohibition in school was strictly enforced
Number of subjects: 1736
Study 24377635 — intervention group
Group type: EXPERIMENTAL
Intervention: Had never seen friends smoking in a school compound
Number of subjects: 1736
Study 21445573 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection surgery (G1)
Number of subjects: 60
Study 21445573 — intervention group
Group type: COMPARATOR
Intervention: Control group (G2)
Number of subjects: 60
Study 19305020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg and Simvastatin 40 mg (coadministered)
Number of subjects: 16
Study 19305020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17365949 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-based coping skills condition (including autogenic training, imagery, and self‐talk)
Number of subjects: 35
Study 17365949 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-based coping skills condition
Number of subjects: 35
Study 17365949 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study 15125120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless, hemispherical, modular, titanium acetabular cup
Number of subjects: 115
Study 15125120 — intervention group
Group type: COMPARATOR
Intervention: Cemented, all‐polyethylene cup
Number of subjects: 115
Study 11704900 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 120
Study 11704900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 120
Study 11704900 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 120
Study 11704900 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy (general)
Number of subjects: 120
Study 9491231 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg once daily for 7 days)
Number of subjects: 12
Study 9491231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9491231 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 12
Study 7840417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine racemate (1 mg/kg)
Number of subjects: 16
Study 7840417 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (0.5 mg/kg)
Number of subjects: 16
Study 2974675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 micrograms
Number of subjects: 24
Study 2974675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 100 micrograms
Number of subjects: 24
Study 2974675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 200 micrograms
Number of subjects: 24
Study 2974675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29723928 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 473
Study 29723928 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 473
Study 29723928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydro-aripiprazole
Number of subjects: 473
Study 29723928 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 473
Study 29723928 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 473
Study 29723928 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 473
Study 29723928 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 473
Study 29723928 — intervention group
Group type: COMPARATOR
Intervention: Agomelatine
Number of subjects: 473
Study 28662281 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly provider funnel plot feedback reports and semiannual face‐to‐face coaching sessions for 12 months
Number of subjects: 25
Study 28662281 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 25970080 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation in addition to comprehensive medical treatment
Number of subjects: 51
Study 25970080 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive medical treatment alone (Control)
Number of subjects: 51
Study 25970080 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell transplantation
Number of subjects: 51
Study 24165815 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified protocol (flattening and enclosing serrated polyps in a paper envelope before placing in formalin)
Number of subjects: 264
Study 24165815 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified protocol
Number of subjects: 264
Study 24165815 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 264
Study 21245070 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Optical Entry (DOE)
Number of subjects: 168
Study 21245070 — intervention group
Group type: COMPARATOR
Intervention: Open Laparoscopy (OL)
Number of subjects: 168
Study 19551674 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily for 12 weeks
Number of subjects: 70
Study 16713661 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 128
Study 16713661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 15214959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin plus rifampicin (400 mg/day plus 600 mg/day for 30 days)
Number of subjects: 29